Observational studyPloS one2022
Chronic kidney disease in cancer patients, the analysis of a large oncology database from Eastern Europe.
Observational study in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Prediction of Acute Kidney Injury in Oncology: From Clinical Risk Scores to AI-Enabled Precision Onco-Nephrology.Cancers · 2026Review
- Deaths Mentioning Both Pancreatic Cancer and Renal Failure in the United States, 1999-2024: Temporal Trends and Disparities.Epidemiologia (Basel, Switzerland) · 2026Article
- Androgen deprivation therapy and kidney function in patients with prostate cancer: an analysis of the RADICAL-PC cohort.International urology and nephrology · 2026Article
- Risk factors for anticoagulant-related bleeding in cancer: traditional and cancer-specific factors.Blood vessels, thrombosis & hemostasis · 2026Article
- Article
- Redefining Chemotherapy-Related Headaches: From Pathobiology to Differential Diagnosis and Management.International journal of molecular sciences · 2025Review
- Knowledge mapping and visualized analysis of research progress in onconephrology: a bibliometric analysis.Renal failure · 2025Article
- Performance of Creatinine and Cystatin-Based Equations on Estimating Measured GFR in People with Hematological and Solid Cancers.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Remote organ cancer induces kidney injury, inflammation, and fibrosis and adversely alters renal function.American journal of physiology. Renal physiology · 2025Article
- Association between intraoperative fluid management and postoperative outcomes in living kidney donors: a retrospective cohort study.Scientific reports · 2025Article
- Characteristics Associated with Length of Stay in Intensive Care Unit for Cancer Patients in China: A Nationwide Retrospective Cohort Study.Journal of multidisciplinary healthcare · 2025Article
- Comparative study of eGFR in cancer and non-cancer individuals: a multicenter analysis.Frontiers in medicine · 2025Article
- Hepatitis C Virus Infection in Hemodialysis Patients in the Era of Direct-Acting Antiviral Treatment: Observational Study and Narrative Review.Medicina (Kaunas, Lithuania) · 2024Observational
- Prevalence of kidney disease in patients with different types of cancer or hematological malignancies: a cross-sectional study.International urology and nephrology · 2024Article
- Sex differences in cancer outcomes across the range of eGFR.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Article
- The Impact of Chronic Kidney Disease on the Mortality Rates of Patients with Urological Cancers-An Analysis of a Uro-Oncology Database from Eastern Europe.Journal of personalized medicine · 2023Article
- Anti-coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug-Drug Interactions.Clinical pharmacokinetics · 2023Review
- The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionKidney dysfunction is prevalent in oncology patients and has an impact on their treatment and quality of life. The aim of our study was to analyze the prevalence of CKD in a large cohort of several types of cancer patients in an East European Region. MATERIAL AND
methodsWe conducted an observational retrospective cohort study on 5831 consecutive, biopsy-diagnosed cancer patients between January 2019 -December 2020 in the largest oncology hospital and outpatient clinic in Western Romania. 4342 subjects were included in the statistical analysis. RESULTS AND DISCUSSION: From the 24 cancer types, the most prevalent cancers were represented by: breast (22.02%), lung (10.18%) and colonic cancer (9.51%). The prevalence of CKD (G3 -G5) was 12.27% after the first year of follow-up and 13.42 after the second year. The prevalence of CKD was higher in patients with renal (50%), urinary tract (33.6%) and pancreatic cancers (19.6%) and lower in patients with colonic cancers (5.3%) and brain tumors (2.5%). At the end of our 2-year survey period, 0,7% of the CKD cases had an eGFR around 6 ml/min/1.73m2 -an indication for renal replacement therapy.
conclusionOncology patients have a significantly higher prevalence of CKD compared to the general population, dependent of the age of the patients and the type of cancer. The prevalence of advanced CKD was surprisingly high (stages G4-G5 Pre-Dialysis 22.15%) one third of the CKD- G5 patients having indication for initiation of renal replacement therapy. An onco- nephrology team should be needed for the best medical care of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.